mutLBSgeneDB |
Gene summary for MAPK9 |
Gene summary |
Basic gene Info. | Gene symbol | MAPK9 |
Gene name | mitogen-activated protein kinase 9 | |
Synonyms | JNK-55|JNK2|JNK2A|JNK2ALPHA|JNK2B|JNK2BETA|PRKM9|SAPK|SAPK1a|p54a|p54aSAPK | |
Cytomap | UCSC genome browser: 5q35 | |
Type of gene | protein-coding | |
RefGenes | NM_001135044.1, NM_002752.4,NM_139068.2,NM_139069.2,NM_139070.2, | |
Description | Jun kinaseMAP kinase 9MAPK 9c-Jun N-terminal kinase 2c-Jun kinase 2stress-activated protein kinase 1astress-activated protein kinase JNK2 | |
Modification date | 20141207 | |
dbXrefs | MIM : 602896 | |
HGNC : HGNC | ||
Ensembl : ENSG00000050748 | ||
HPRD : 04206 | ||
Vega : OTTHUMG00000130934 | ||
Protein | UniProt: P45984 go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_MAPK9 | |
BioGPS: 5601 | ||
Pathway | NCI Pathway Interaction Database: MAPK9 | |
KEGG: MAPK9 | ||
REACTOME: MAPK9 | ||
Pathway Commons: MAPK9 | ||
Context | iHOP: MAPK9 | |
ligand binding site mutation search in PubMed: MAPK9 | ||
UCL Cancer Institute: MAPK9 | ||
Assigned class in mutLBSgeneDB | B: This gene belongs to targetable_mutLBSgenes. |
Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
GO ID | GO Term | PubMed ID | GO:0007254 | JNK cascade | 8654373 |
Top |
Ligand binding site mutations for MAPK9 |
Cancer type specific mutLBS sorted by frequency |
LBS | AAchange of nsSNV | Cancer type | # samples | K55 | K56E | COAD | 2 | K55 | K56R | COAD | 2 | L142 | H143L | HNSC | 1 | L77 | C79F | LUAD | 1 | E73 | R72C | SKCM | 1 | N114 | C116Y | STAD | 1 | K55,A53 | V54D | STAD | 1 | R69 | A67T | UCEC | 1 | E109 | E109K | UCEC | 1 |
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
Top |
Protein structure related information for MAPK9 |
Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
: nsSNV at non-LBS: nsSNV at LBS |
nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
LBS | AAchange of nsSNV | Relative stability change | E73 | R72C | 0.14617348 | K55 | V54D | -1.6087828 | A53 | V54D | -1.6087828 | E109 | E109K | -1.2344024 | L77 | C79F | -0.94448751 | N114 | C116Y | -0.9233146 | R69 | A67T | -0.63213118 | K55 | K56E | -0.25808379 | K55 | K56R | -0.17107702 | L142 | H143L | -0.16623519 |
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
Structure image for MAPK9 from PDB |
PDB ID | PDB title | PDB structure | 3E7O | Crystal Structure of JNK2 |
Top |
Differential gene expression and gene-gene network for MAPK9 |
Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
Top |
Top |
Phenotype information for MAPK9 |
Gene level disease information (DisGeNet) |
Disease ID | Disease name | # PubMed | Association type |
umls:C0032927 | Precancerous Conditions | 2 | Biomarker |
umls:C0035126 | Reperfusion Injury | 2 | Biomarker |
umls:C0022116 | Ischemia | 1 | Biomarker |
umls:C0027055 | Myocardial Reperfusion Injury | 1 | Biomarker |
umls:C0027627 | Neoplasm Metastasis | 1 | Therapeutic |
Mutation level pathogenic information (ClinVar annotation) |
Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
Top |
Pharmacological information for MAPK9 |
Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
Gene-centered drug-gene interaction network |
Drug information targeting mutLBSgene (Approved drugs only) |
Drug status | DrugBank ID | Name | Type | Drug structure |
Experimental | DB07020 | N-{3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]phenyl}furan-2-carboxamide | Small molecule |
Gene-centered ligand-gene interaction network |
Ligands binding to mutated ligand binding site of MAPK9 go to BioLip |
Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | 35F | N-{3-[5-(1H-1,2,4-TRIAZOL-3-YL)-1H-INDAZOL-3-YL]PHENYL}FURAN-2-CARBOXAMIDE | 3e7o | B | A53 E109 | 35F | N-{3-[5-(1H-1,2,4-TRIAZOL-3-YL)-1H-INDAZOL-3-YL]PHENYL}FURAN-2-CARBOXAMIDE | 3e7o | A | A53 E109 N114 | B96 | 1-(5-TERT-BUTYL-2-P-TOLYL-2H-PYRAZOL-3-YL)-3-[4-(2-MORPHOLIN-4-YL-ETHOXY)-NAPHTHALEN-1-YL]-UREA | 3npc | B | A53 K55 R69 E73 L77 | B96 | 1-(5-TERT-BUTYL-2-P-TOLYL-2H-PYRAZOL-3-YL)-3-[4-(2-MORPHOLIN-4-YL-ETHOXY)-NAPHTHALEN-1-YL]-UREA | 3npc | A | A53 K55 R69 E73 L77 L142 |
Top |
Conservation information for LBS of MAPK9 |
Multiple alignments for P45984 in multiple species |
LBS | AA sequence | # species | Species | A113 | MELMDANLCQV | 4 | Homo sapiens, Gallus gallus, Mus musculus, Rattus norvegicus | A53 | LGINVAVKKLS | 4 | Homo sapiens, Gallus gallus, Mus musculus, Rattus norvegicus | D112 | VMELMDANLCQ | 4 | Homo sapiens, Gallus gallus, Mus musculus, Rattus norvegicus | D169 | TLKILDFGLAR | 4 | Homo sapiens, Gallus gallus, Mus musculus, Rattus norvegicus | E109 | VYLVMELMDAN | 4 | Homo sapiens, Gallus gallus, Mus musculus, Rattus norvegicus | E73 | KRAYRELVLLK | 4 | Homo sapiens, Gallus gallus, Mus musculus, Rattus norvegicus | F170 | LKILDFGLART | 4 | Homo sapiens, Gallus gallus, Mus musculus, Rattus norvegicus | I32 | QQLKPIGSGAQ | 4 | Homo sapiens, Gallus gallus, Mus musculus, Rattus norvegicus | I86 | NHKNIISLLNV | 4 | Homo sapiens, Gallus gallus, Mus musculus, Rattus norvegicus | K55 | INVAVKKLSRP | 4 | Homo sapiens, Gallus gallus, Mus musculus, Rattus norvegicus | L106 | FQDVYLVMELM | 4 | Homo sapiens, Gallus gallus, Mus musculus, Rattus norvegicus | L110 | YLVMELMDANL | 4 | Homo sapiens, Gallus gallus, Mus musculus, Rattus norvegicus | L142 | CGIKHLHSAGI | 4 | Homo sapiens, Gallus gallus, Mus musculus, Rattus norvegicus | L168 | CTLKILDFGLA | 4 | Homo sapiens, Gallus gallus, Mus musculus, Rattus norvegicus | L76 | YRELVLLKCVN | 4 | Homo sapiens, Gallus gallus, Mus musculus, Rattus norvegicus | L77 | RELVLLKCVNH | 4 | Homo sapiens, Gallus gallus, Mus musculus, Rattus norvegicus | M108 | DVYLVMELMDA | 4 | Homo sapiens, Gallus gallus, Mus musculus, Rattus norvegicus | M111 | LVMELMDANLC | 4 | Homo sapiens, Gallus gallus, Mus musculus, Rattus norvegicus | N114 | ELMDANLCQVI | 4 | Homo sapiens, Gallus gallus, Mus musculus, Rattus norvegicus | R69 | QTHAKRAYREL | 4 | Homo sapiens, Gallus gallus, Mus musculus, Rattus norvegicus | V158 | KPSNIVVKSDC | 4 | Homo sapiens, Gallus gallus, Mus musculus, Rattus norvegicus | V40 | GAQGIVCAAFD | 4 | Homo sapiens, Gallus gallus, Mus musculus, Rattus norvegicus |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |